<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01315236</url>
  </required_header>
  <id_info>
    <org_study_id>TR02-112</org_study_id>
    <nct_id>NCT01315236</nct_id>
  </id_info>
  <brief_title>Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Insmed Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Insmed Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety and tolerability of 84 days of
      daily dosing of 590 mg of LAI versus placebo in patients with treatment refractory NTM lung
      disease.

      The first part of the study is the 84-day double-blind phase to evaluate the primary and
      secondary endpoints.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase 2, randomized, double-blind study of efficacy, safety, and tolerability of
      once daily (QD) dosing of LAI 590 mg versus placebo for 84 days in subjects with treatment
      refractory NTM lung infection on a stable multidrug regimen. At the conclusion of the
      randomized double-blind phase of the study, subjects who consented to continue in the
      open-label phase of the study received LAI 590 mg QD for 84 additional days. All subjects
      were required to complete a 28-day safety follow-up after their end of treatment study visit
      (Day 168). Subjects completing this study were consented for enrollment in a long-term
      follow-up phase and were asked to return to the study site at 12 months and 24 months (per
      protocol Amendment #3, the 24-month follow-up visit was no longer required) (visit window ± 2
      months) after the last dose of study drug (either after completing the randomized
      double-blind phase or the open-label phase). Subjects were stratified upon entering the study
      based on the presence or absence of cystic fibrosis (CF) and Mycobacterium avium complex
      versus M abscessus as the predominate NTM organism at baseline and were block randomized to
      receive either LAI or placebo in a 1:1 ratio in the double-blind phase.

      Subjects completing the main study, and subjects who completed the 84-day open-label phase,
      were consented for enrollment in a post-LAI safety follow-up assessment and were asked to
      return to the study site 12 months (visit window ± 2 months) after the last dose of study
      drug (either after completing the randomized double-blind phase or the open-label phase). The
      screening period required obtaining 3 morning sputum specimens (spontaneous or induced) for
      mycobacteriology. At each post-screening sputum timepoint, at least 2 and preferably 3 sputum
      specimens were obtained. At Day 1 (baseline), subjects were evaluated pre-dose and post-dose
      at the study site. Subjects returned to the study site briefly on Day 2 for collection of
      serum samples to determine creatinine clearance. On Days 28, 56, and 84, study drug was
      administered at the site and the efficacy, safety, and tolerability of study drug were
      evaluated. At Day 85, those subjects continuing in the open-label phase of the study received
      LAI 590 mg at the study site with pre-dose and post-dose assessments for safety and efficacy.
      Subjects returned every 28 days (Days 112, 140, and 168) in the open-label phase. A 28-day,
      post-dose follow-up visit occurred at either Day 112 for those subjects who did not continue
      in the open-label phase or at Day 196 for those subjects who continued in the open-label
      phase.

      Subjects completing the main study, and subjects who completed the 84-day open-label phase,
      were consented for enrollment in a post-LAI safety follow-up assessment and were asked to
      return to the study site 12 months (visit window ± 2 months) after the last dose of study
      drug (either after completing the randomized double-blind phase or the open-label phase).
      Arikace™, Arikayce™, Liposomal Amikacin for Inhalation (LAI), and Amikacin Liposome
      Inhalation Suspension (ALIS) may be used interchangeably throughout this study and other
      studies evaluating amikacin liposome inhalation suspension.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 19, 2012</start_date>
  <completion_date type="Actual">June 18, 2015</completion_date>
  <primary_completion_date type="Actual">August 18, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Semi-Quantitative Mycobacterial Culture Results From Baseline to Day 84.</measure>
    <time_frame>Baseline and end of double-blind phase of 84 days</time_frame>
    <description>The endpoint used the 7-step semi-quantitative scale (SQS) for mycobacterial culture reporting in both solid and liquid growth media, with step 1 = culture negative in both solid and liquid media, step 2 = growth in liquid medium only, 3 = solid medium positive, 4 = 50 to 100 colonies in solid medium &amp; growth in liquid, 5 = &gt;100 to 200 colonies in solid medium &amp; growth in liquid, 6 = &gt;200 to 500 colonies in solid medium &amp; growth in liquid, 7 = &gt;500 colonies in solid medium &amp; growth in liquid. Full scale range is 1 (best score) to 7 (worst score). The change in step measures the growth at Day 84 compared to the growth at Baseline. The negative values represent reduction in colony growth.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Negative NTM Culture for the LAI Arm at Day 84 Compared to the Placebo Arm at Day 84</measure>
    <time_frame>84 days double-blind phase</time_frame>
    <description>Sputum specimens were cultured in liquid media in addition to solid media (agar). If results were negative on agar, the liquid media was held for 6 weeks before reporting as culture negative. Culture was negative when confirmed with no growth in liquid medium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Negative NTM Culture….During the 84-day Double-blind Treatment Phase</measure>
    <time_frame>84 days double-blind phase</time_frame>
    <description>Sputum specimens were cultured in liquid media in addition to solid media (agar). If results were negative on agar, the liquid media was held for 6 weeks before reporting as culture negative. Culture was negative when confirmed with no growth in liquid medium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ordinal, 3-level Response From Baseline on the SQS for Mycobacterial Culture for the LAI Arm at Day 84 Compared to the Placebo Arm at Day 84</measure>
    <time_frame>Baseline and end of double-blind phase of 84 days</time_frame>
    <description>The ordinal, 3-level response are (1) improvement (2) no change (3) worsening or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Respiratory and Systemic Symptoms Questionnaire (RSSQ) Score at Day 84 for the LAI Arm Compared to the Placebo Arm</measure>
    <time_frame>Baseline to day 84.</time_frame>
    <description>The RSSQ was administered to gather information from the subject about the types of symptoms that the subject has experienced since the last contact. A reduction in score indicates improvement. The range of values for the scores are -2 (best) to +2 (worst) in whole numbers. The composite score was calculated by averaging the scores of the subscales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Global Rating of Health (GRH) at Day 84 for the LAI Arm Compared to the Placebo Arm</measure>
    <time_frame>Baseline and end of double-blind phase of 84 days</time_frame>
    <description>The assessing physician asked the subject to rate his/her assessment of health according to the GRH. Subject responses to, &quot;How would you rate your health at the present time?&quot; included: Excellent, Good, Fair, or Poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Requiring &quot;Rescue&quot; Anti-mycobacterial or Other &quot;Rescue&quot; Drugs During the 84-day Double-blind Phase</measure>
    <time_frame>84 days double-blind phase</time_frame>
    <description>Per the study protocol, study subjects were on a stable, multi-drug, anti-mycobacterial regimen based on the 2007 ATS/IDSA Guidelines; the regimen should not have changed during the study period except for safety concerns. The need for changes to the concurrent anti-mycobacterial regimen or &quot;rescue&quot; therapy was at the discretion of the Investigator and was tracked as a study outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subject for &quot;Rescue&quot; Anti-mycobacterial or Other &quot;Rescue&quot; Drugs During the 84-day Double-blind Phase</measure>
    <time_frame>84 days double-blind phase</time_frame>
    <description>Per the study protocol, study subjects were on a stable, multi-drug, anti-mycobacterial regimen based on the 2007 ATS/IDSA Guidelines; the regimen should not have changed during the study period except for safety concerns. The need for changes to the concurrent anti-mycobacterial regimen or &quot;rescue&quot; therapy was at the discretion of the Investigator and was tracked as a study outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Mycobacterium Infections, Nontuberculous</condition>
  <arm_group>
    <arm_group_label>LAI 590 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LAI 590 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal amikacin for inhalation (LAI)</intervention_name>
    <description>Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.
Subjects can continue with 84 additional days of dosing in the open label extension.</description>
    <arm_group_label>LAI 590 mg QD</arm_group_label>
    <other_name>Amikacin Liposome Inhalation Suspension (ALIS)</other_name>
    <other_name>Arikayce</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.
Administration procedures, volume and administration time are similar to LAI.
Placebo will be administered for 84 days only during the double-blind, randomized portion of the study.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Diagnosis of pulmonary nontuberculous mycobacterial lung disease in accordance with
             the 2007 ATS/IDSA criteria with evidence of nodular bronchiectasis and/or cavitary
             disease by chest computed tomography (CT).

          2. History of chronic infection with either Mycobacterium avium complex or Mycobacterium
             abscessus or mixed infection with both species (defined as at least 2 documented
             positive cultures in the prior 2 years, of which at least one was obtained in the 6
             months prior to screening).

          3. Positive sputum culture obtained at screening visit with either Mycobacterium avium
             complex or Mycobacterium abscessus or mixed infection with one dominant species.

          4. Receiving ATS/IDSA guidelines-based treatment regimen defined as: adherent to a
             multi-drug regimen for at least 6 months prior to screening with persistently positive
             mycobacterial cultures.

          5. Ability to produce at least 3 mL of sputum or be willing to undergo an induction that
             produces at least 3 mL of sputum for clinical evaluation.

          6. Female of childbearing potential agrees to practice an acceptable method of birth
             control (e.g., abstinence, hormonal or barrier methods, partner sterilization, or
             IUD).

        Key Exclusion Criteria:

          1. Forced Expiratory Volume in 1 second (FEV1) &lt;30% of predicted at Screening.

          2. Presence of any clinically significant cardiac disease as determined by Investigator.
             The QTc criteria for Exclusion is QTc&gt; 450 msec for males or QTc&gt; 470 msec for
             females.

          3. Subjects with hemoptysis of ≥60 mL in a 24 hour period within 4 weeks prior to
             screening.

          4. Active pulmonary malignancy (primary or metastatic) or any malignancy requiring
             chemotherapy or radiation therapy within one year prior to screening or anticipated
             during the study period.

          5. Active allergic bronchopulmonary mycosis or any other condition requiring systemic
             steroids at a dose &gt; equivalent of 10 mg/day of prednisone within 3 months prior to
             screening or anticipated during the study period.

          6. Pulmonary tuberculosis requiring treatment or treated within 2 years prior to
             screening.

          7. History of lung transplantation.

          8. Hypersensitivity to aminoglycosides.

          9. Any change in chronic NTM multi-drug regimen within 28 days prior to Study Day 1.

         10. Evidence of biliary cirrhosis with portal hypertension.

         11. History of daily, continuous oxygen supplementation.

         12. Smoking tobacco or any substance within 6 months prior to screening or anticipated
             inability to refrain from smoking throughout the study.

        Subjects with CF or primary ciliary dyskinesia were eligible to participate in the study if
        all eligibility criteria defined above were met. Subjects with CF were required to have
        documented confirmation of CF to be eligible for the study. The CF diagnosis had to be
        documented by a positive sweat test ≥ 60 mmol/L or by DNA analysis revealing both mutated
        alleles consistent with CF disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gina Eagle</last_name>
    <role>Study Director</role>
    <affiliation>Insmed Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 11, 2011</study_first_submitted>
  <study_first_submitted_qc>March 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2011</study_first_posted>
  <results_first_submitted>April 3, 2019</results_first_submitted>
  <results_first_submitted_qc>August 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2019</results_first_posted>
  <disposition_first_submitted>September 29, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>September 29, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 3, 2016</disposition_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amikacin Liposome Inhalation Suspension (ALIS)</keyword>
  <keyword>Arikayce</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Mycobacterium Infections, Nontuberculous</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amikacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>One patient out of the 90 was randomized but not dosed.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>LAI 590 mg QD</title>
          <description>LAI 590 mg QD
Liposomal amikacin for inhalation (LAI): - Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.
Subjects can continue with 84 additional days of dosing in the open label extension.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo QD
placebo: - Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.
Administration procedures, volume and administration time are similar to LAI.
Placebo will be administered for 84 days only during the double-blind, randomized portion of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-label Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35">Some subjects did not consent to the open label after the double blind phase.</participants>
                <participants group_id="P2" count="43">Some subjects did not consent to the open label after the double blind phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>12-Month Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27">Some subjects did not consent to the 12 month safety.</participants>
                <participants group_id="P2" count="32">Some subjects did not consent to the 12 month safety.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not return to the site for Month 12</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Double-blind Phase</population>
      <group_list>
        <group group_id="B1">
          <title>LAI 590 mg QD</title>
          <description>LAI 590 mg QD
Liposomal amikacin for inhalation (LAI): - Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.
Subjects can continue with 84 additional days of dosing in the open label extension.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo QD
placebo: - Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.
Administration procedures, volume and administration time are similar to LAI.
Placebo will be administered for 84 days only during the double-blind, randomized portion of the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="89"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.0" spread="16.61"/>
                    <measurement group_id="B2" value="59.1" spread="15.20"/>
                    <measurement group_id="B3" value="58.5" spread="15.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White (not of Hispanic origin)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Semi-Quantitative Mycobacterial Culture Results From Baseline to Day 84.</title>
        <description>The endpoint used the 7-step semi-quantitative scale (SQS) for mycobacterial culture reporting in both solid and liquid growth media, with step 1 = culture negative in both solid and liquid media, step 2 = growth in liquid medium only, 3 = solid medium positive, 4 = 50 to 100 colonies in solid medium &amp; growth in liquid, 5 = &gt;100 to 200 colonies in solid medium &amp; growth in liquid, 6 = &gt;200 to 500 colonies in solid medium &amp; growth in liquid, 7 = &gt;500 colonies in solid medium &amp; growth in liquid. Full scale range is 1 (best score) to 7 (worst score). The change in step measures the growth at Day 84 compared to the growth at Baseline. The negative values represent reduction in colony growth.</description>
        <time_frame>Baseline and end of double-blind phase of 84 days</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>LAI 590 mg QD</title>
            <description>LAI 590 mg QD
Liposomal amikacin for inhalation (LAI): - Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.
Subjects can continue with 84 additional days of dosing in the open label extension.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo QD
placebo: - Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.
Administration procedures, volume and administration time are similar to LAI.
Placebo will be administered for 84 days only during the double-blind, randomized portion of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Semi-Quantitative Mycobacterial Culture Results From Baseline to Day 84.</title>
          <description>The endpoint used the 7-step semi-quantitative scale (SQS) for mycobacterial culture reporting in both solid and liquid growth media, with step 1 = culture negative in both solid and liquid media, step 2 = growth in liquid medium only, 3 = solid medium positive, 4 = 50 to 100 colonies in solid medium &amp; growth in liquid, 5 = &gt;100 to 200 colonies in solid medium &amp; growth in liquid, 6 = &gt;200 to 500 colonies in solid medium &amp; growth in liquid, 7 = &gt;500 colonies in solid medium &amp; growth in liquid. Full scale range is 1 (best score) to 7 (worst score). The change in step measures the growth at Day 84 compared to the growth at Baseline. The negative values represent reduction in colony growth.</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Culture negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Growth in liquid medium only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Agar positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1+ (50-100 colonies)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 2+ (&gt; 100-200 colonies)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 3+ (&gt; 200-500 colonies)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 4+ (&gt; 500 colonies)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84: -6 steps from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84: -5 steps from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84: -4 steps from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84: -3 steps from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84: -2 steps from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84: -1 step from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84: no change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84: +1 step from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84: +2 steps from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84: +3 steps from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84: +4 steps from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84: +5 steps from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84: +6 steps from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84: +7 (Death)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy analysis tested the following hypotheses:
H0: There is no difference at Day 84 between the LAI arm and the placebo arm
Ha: There is a difference at Day 84 between the LAI arm and the placebo arm
Statistical analysis applies to all day 84 rows.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.072</p_value>
            <p_value_desc>Conducted in the mITT population using a stratified Wilcoxon rank sum test, to compare the treatment arms at a 2-sided significance level of 0.05, adjusting for the randomization strata (presence/absence of CF and MAC versus Mycobacterium abscessus).</p_value_desc>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Negative NTM Culture for the LAI Arm at Day 84 Compared to the Placebo Arm at Day 84</title>
        <description>Sputum specimens were cultured in liquid media in addition to solid media (agar). If results were negative on agar, the liquid media was held for 6 weeks before reporting as culture negative. Culture was negative when confirmed with no growth in liquid medium.</description>
        <time_frame>84 days double-blind phase</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>LAI 590 mg QD</title>
            <description>LAI 590 mg QD
Liposomal amikacin for inhalation (LAI): - Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.
Subjects can continue with 84 additional days of dosing in the open label extension.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo QD
placebo: - Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.
Administration procedures, volume and administration time are similar to LAI.
Placebo will be administered for 84 days only during the double-blind, randomized portion of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Negative NTM Culture for the LAI Arm at Day 84 Compared to the Placebo Arm at Day 84</title>
          <description>Sputum specimens were cultured in liquid media in addition to solid media (agar). If results were negative on agar, the liquid media was held for 6 weeks before reporting as culture negative. Culture was negative when confirmed with no growth in liquid medium.</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>stratified Cochran-Mantel-Haenszel test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Negative NTM Culture….During the 84-day Double-blind Treatment Phase</title>
        <description>Sputum specimens were cultured in liquid media in addition to solid media (agar). If results were negative on agar, the liquid media was held for 6 weeks before reporting as culture negative. Culture was negative when confirmed with no growth in liquid medium.</description>
        <time_frame>84 days double-blind phase</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>LAI 590 mg QD</title>
            <description>LAI 590 mg QD
Liposomal amikacin for inhalation (LAI): - Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.
Subjects can continue with 84 additional days of dosing in the open label extension.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo QD
placebo: - Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.
Administration procedures, volume and administration time are similar to LAI.
Placebo will be administered for 84 days only during the double-blind, randomized portion of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Negative NTM Culture….During the 84-day Double-blind Treatment Phase</title>
          <description>Sputum specimens were cultured in liquid media in addition to solid media (agar). If results were negative on agar, the liquid media was held for 6 weeks before reporting as culture negative. Culture was negative when confirmed with no growth in liquid medium.</description>
          <population>mITT</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="85.0" upper_limit="NA">The median time to a negative NTM culture was not able to be estimated due to insufficient number of participants.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">The median time to a negative NTM culture was not able to be estimated due to insufficient number of participants.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cox proportional hazard model</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0129</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>5.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.25</ci_lower_limit>
            <ci_upper_limit>25.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ordinal, 3-level Response From Baseline on the SQS for Mycobacterial Culture for the LAI Arm at Day 84 Compared to the Placebo Arm at Day 84</title>
        <description>The ordinal, 3-level response are (1) improvement (2) no change (3) worsening or death</description>
        <time_frame>Baseline and end of double-blind phase of 84 days</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>LAI 590 mg QD</title>
            <description>LAI 590 mg QD
Liposomal amikacin for inhalation (LAI): - Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.
Subjects can continue with 84 additional days of dosing in the open label extension.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo QD
placebo: - Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.
Administration procedures, volume and administration time are similar to LAI.
Placebo will be administered for 84 days only during the double-blind, randomized portion of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Ordinal, 3-level Response From Baseline on the SQS for Mycobacterial Culture for the LAI Arm at Day 84 Compared to the Placebo Arm at Day 84</title>
          <description>The ordinal, 3-level response are (1) improvement (2) no change (3) worsening or death</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improvement (a decrease of 1 step or more)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening (an increase of 1 step or more) or death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ordinal Logistic Regressions Model</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.077</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Respiratory and Systemic Symptoms Questionnaire (RSSQ) Score at Day 84 for the LAI Arm Compared to the Placebo Arm</title>
        <description>The RSSQ was administered to gather information from the subject about the types of symptoms that the subject has experienced since the last contact. A reduction in score indicates improvement. The range of values for the scores are -2 (best) to +2 (worst) in whole numbers. The composite score was calculated by averaging the scores of the subscales.</description>
        <time_frame>Baseline to day 84.</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>LAI 590 mg QD</title>
            <description>LAI 590 mg QD
Liposomal amikacin for inhalation (LAI): - Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.
Subjects can continue with 84 additional days of dosing in the open label extension.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo QD
placebo: - Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.
Administration procedures, volume and administration time are similar to LAI.
Placebo will be administered for 84 days only during the double-blind, randomized portion of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Respiratory and Systemic Symptoms Questionnaire (RSSQ) Score at Day 84 for the LAI Arm Compared to the Placebo Arm</title>
          <description>The RSSQ was administered to gather information from the subject about the types of symptoms that the subject has experienced since the last contact. A reduction in score indicates improvement. The range of values for the scores are -2 (best) to +2 (worst) in whole numbers. The composite score was calculated by averaging the scores of the subscales.</description>
          <population>mITT</population>
          <units>units on a score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.992"/>
                    <measurement group_id="O2" value="-0.60" spread="0.736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified Wilcoxon-rank sum</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4545</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Global Rating of Health (GRH) at Day 84 for the LAI Arm Compared to the Placebo Arm</title>
        <description>The assessing physician asked the subject to rate his/her assessment of health according to the GRH. Subject responses to, &quot;How would you rate your health at the present time?&quot; included: Excellent, Good, Fair, or Poor.</description>
        <time_frame>Baseline and end of double-blind phase of 84 days</time_frame>
        <population>mITT
Subjects with missing data were excluded</population>
        <group_list>
          <group group_id="O1">
            <title>LAI 590 mg QD</title>
            <description>LAI 590 mg QD
Liposomal amikacin for inhalation (LAI): - Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.
Subjects can continue with 84 additional days of dosing in the open label extension.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo QD
placebo: - Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.
Administration procedures, volume and administration time are similar to LAI.
Placebo will be administered for 84 days only during the double-blind, randomized portion of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Global Rating of Health (GRH) at Day 84 for the LAI Arm Compared to the Placebo Arm</title>
          <description>The assessing physician asked the subject to rate his/her assessment of health according to the GRH. Subject responses to, &quot;How would you rate your health at the present time?&quot; included: Excellent, Good, Fair, or Poor.</description>
          <population>mITT
Subjects with missing data were excluded</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No change: Excellent -&gt; Excellent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change: Good -&gt; Good</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change: Fair -&gt; Fair</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change: Poor -&gt; Poor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase: By 3 Categories (Poor -&gt; Excellent)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase by 2 Categories</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase: By 2 Categories (Poor -&gt; Good)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase: By 2 Categories (Fair -&gt; Excellent)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase by 1 Category</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase: By 1 Category (Poor -&gt; Fair)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase: By 1 Category (Fair -&gt; Good)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase: By 1 Category (Good -&gt; Excellent)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease: By 3 Categories (Excellent --&gt; Poor)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease: By 2 Categories</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease: By 2 Categories (Excellent -&gt; Fair)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease: By 2 Categories (Good -&gt; Poor)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease: By 1 Category</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease: By 1 Category (Excellent -&gt; Good)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease: By 1 Category (Good -&gt; Fair)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease: By 1 Category (Fair -&gt; Poor)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Requiring &quot;Rescue&quot; Anti-mycobacterial or Other &quot;Rescue&quot; Drugs During the 84-day Double-blind Phase</title>
        <description>Per the study protocol, study subjects were on a stable, multi-drug, anti-mycobacterial regimen based on the 2007 ATS/IDSA Guidelines; the regimen should not have changed during the study period except for safety concerns. The need for changes to the concurrent anti-mycobacterial regimen or &quot;rescue&quot; therapy was at the discretion of the Investigator and was tracked as a study outcome.</description>
        <time_frame>84 days double-blind phase</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>LAI 590 mg QD</title>
            <description>LAI 590 mg QD
Liposomal amikacin for inhalation (LAI): - Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.
Subjects can continue with 84 additional days of dosing in the open label extension.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo QD
placebo: - Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.
Administration procedures, volume and administration time are similar to LAI.
Placebo will be administered for 84 days only during the double-blind, randomized portion of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Requiring &quot;Rescue&quot; Anti-mycobacterial or Other &quot;Rescue&quot; Drugs During the 84-day Double-blind Phase</title>
          <description>Per the study protocol, study subjects were on a stable, multi-drug, anti-mycobacterial regimen based on the 2007 ATS/IDSA Guidelines; the regimen should not have changed during the study period except for safety concerns. The need for changes to the concurrent anti-mycobacterial regimen or &quot;rescue&quot; therapy was at the discretion of the Investigator and was tracked as a study outcome.</description>
          <population>mITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cox Proportional Hazard Model</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0076</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>2.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.28</ci_lower_limit>
            <ci_upper_limit>5.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subject for &quot;Rescue&quot; Anti-mycobacterial or Other &quot;Rescue&quot; Drugs During the 84-day Double-blind Phase</title>
        <description>Per the study protocol, study subjects were on a stable, multi-drug, anti-mycobacterial regimen based on the 2007 ATS/IDSA Guidelines; the regimen should not have changed during the study period except for safety concerns. The need for changes to the concurrent anti-mycobacterial regimen or &quot;rescue&quot; therapy was at the discretion of the Investigator and was tracked as a study outcome.</description>
        <time_frame>84 days double-blind phase</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>LAI 590 mg QD</title>
            <description>LAI 590 mg QD
Liposomal amikacin for inhalation (LAI): - Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.
Subjects can continue with 84 additional days of dosing in the open label extension.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo QD
placebo: - Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.
Administration procedures, volume and administration time are similar to LAI.
Placebo will be administered for 84 days only during the double-blind, randomized portion of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subject for &quot;Rescue&quot; Anti-mycobacterial or Other &quot;Rescue&quot; Drugs During the 84-day Double-blind Phase</title>
          <description>Per the study protocol, study subjects were on a stable, multi-drug, anti-mycobacterial regimen based on the 2007 ATS/IDSA Guidelines; the regimen should not have changed during the study period except for safety concerns. The need for changes to the concurrent anti-mycobacterial regimen or &quot;rescue&quot; therapy was at the discretion of the Investigator and was tracked as a study outcome.</description>
          <population>mITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of subjects with the event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 196 (84 days double-blind phase + 84 days open label phase + 28 days post discontinuation of study drug). Adverse events (AEs) were not collected during the 12-month follow-up period..</time_frame>
      <group_list>
        <group group_id="E1">
          <title>LAI 590 mg QD - Double Blind</title>
          <description>LAI 590 mg QD
Liposomal amikacin for inhalation (LAI): - Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.
Subjects can continue with 84 additional days of dosing in the open label extension.</description>
        </group>
        <group group_id="E2">
          <title>Placebo - Double Blind</title>
          <description>placebo QD
placebo: - Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.
Administration procedures, volume and administration time are similar to LAI.
Placebo will be administered for 84 days only during the double-blind, randomized portion of the study.</description>
        </group>
        <group group_id="E3">
          <title>LAI 590 mg QD - Open Label</title>
          <description>LAI 590 mg QD
Liposomal amikacin for inhalation (LAI): - Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
- 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Subjects can continue with 84 additional days of dosing in the open label extension.</description>
        </group>
        <group group_id="E4">
          <title>Placebo - Open Label</title>
          <description>placebo QD
placebo: - Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.
Subjects can continue with 84 additional days of dosing in the open label extension.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infective exacerbation of bronchiectasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Infective pulmonary exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Eosinophilic pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infective exacerbation of bronchiectasis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="44"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="35"/>
                <counts group_id="E4" events="16" subjects_affected="15" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Infective pulmonary exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Aphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="44"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="44"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Per the signed Investigator Agreement in the protocol and protocol amendments, the PI agreed that the information presented in the study protocol is confidential, and assured that no information based on the conduct of the study was released without prior Insmed Incorporated Consent, unless the requirement is superseded by the Food and Drug Administration or other regulatory authority.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kevin Mange (Senior VP, Clinical Development)</name_or_title>
      <organization>Insmed Incorporated</organization>
      <phone>908-947-2651</phone>
      <email>kevin.mange@insmed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

